Business Context and Reporting Period
This Form 8-K is a current report filed by RXi Pharmaceuticals Corporation (also referenced as Phio Pharmaceuticals Corp. in metadata) on September 15, 2017. The report discloses a material corporate event regarding executive leadership changes effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Departure: Alexey Eliseev's employment as Chief Business Officer ended effective September 15, 2017.
- Termination Status: The departure is classified as a termination without cause under the Employment Agreement dated January 6, 2017.
- Compensation: Dr. Eliseev is entitled to receive severance benefits consistent with the terms and conditions of his Employment Agreement.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk factors beyond the immediate impact of the executive departure. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the specific terms of the severance package for Dr. Eliseev in the Employment Agreement dated January 6, 2017.
- Confirm whether a successor has been appointed to the Chief Business Officer role.
- Review subsequent filings for any financial impact related to the severance payment.